Pulmonology prior authorization at Regence
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Regence pulmonology PA at a glance
Regence reviews pulmonology PA submissions against its medical policy library, with rules drawn primarily from GINA (Global Initiative for Asthma) + ERS-ATS (IPF) + Cystic Fibrosis Foundation. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet — what to send
- Diagnosis with ICD-10 (severe asthma, IPF, CF)
- Spirometry (FEV1, FVC, FEV1/FVC)
- Biomarker thresholds (eos, IgE, FeNO)
- Genotype for CF modulators
- HRCT for IPF with pattern interpretation
- Maximal controller therapy documentation
Common denial patterns to pre-empt
Patterns observed in pulmonology across payers, and where Regence's book of business overlaps:
- Severe asthma biologic: eosinophil threshold not met (varies by drug)
- Severe asthma biologic: not on maximal controller therapy (high-dose ICS-LABA)
- CFTR modulators: genotype documentation missing
- Antifibrotics (IPF): diagnosis not confirmed by HRCT pattern + multidisciplinary discussion
- Site-of-care reduction
- Step therapy via Prime Therapeutics
Appeal angles when Regence denies
- GINA (asthma) / ERS-ATS (IPF) / CFF (CF) guideline citation
- Eosinophil count + IgE + FeNO documentation supporting biologic phenotype
- Genetic CFTR mutation report for CF modulators
- HRCT pattern documentation + MDD note for IPF antifibrotics
Peer-to-peer prep
- Have the most recent spirometry + biomarker labs open
- For CF modulators: confirm the genotype matches the FDA label (e.g. F508del homozygous, heterozygous, or responsive variants)
- For IPF: emphasise the MDD diagnosis and HRCT pattern (UIP, probable UIP)
- Quote GINA severity step (3-5) for severe asthma biologics
Drug-specific PA criteria at Regence
Deep dives on each drug's PA criteria at Regence:
Frequently asked questions
What documentation does Regence need for pulmonology prior authorizations?
Regence's PA packet for pulmonology typically includes: Diagnosis with ICD-10 (severe asthma, IPF, CF); Spirometry (FEV1, FVC, FEV1/FVC); Biomarker thresholds (eos, IgE, FeNO); Genotype for CF modulators. GINA (Global Initiative for Asthma) + ERS-ATS (IPF) + Cystic Fibrosis Foundation citations strengthen the submission.
What's the turnaround at Regence?
Regence standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which pulmonology drugs does Regence most often PA-restrict?
Top targets in pulmonology: dupilumab, mepolizumab, omalizumab, tezepelumab, elexacaftor tezacaftor ivacaftor. Each follows the per-drug step therapy + documentation requirements published in Regence's medical policy library.
How do I prep a peer-to-peer with Regence in pulmonology?
Have the most recent spirometry + biomarker labs open For CF modulators: confirm the genotype matches the FDA label (e.g. F508del homozygous, heterozygous, or responsive variants) Have the policy URL and the patient's chart open before the call.
Generate a Pulmonology PA packet
Open ApprovalHelp — generate a pulmonology PA packet tailored to Regence's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com